A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 7, 2010, Pages 683-694

  Ajmani, Subhash ^a   Agrawal, Avantika ^a   Kulkarni, Sudhir A ^a  

^a NovaLead Pharma Pvt Ltd   (India)

Author keywords

Akt inhibitors; Anticancer; Kinase inhibitors; Protein kinase B; QSAR

Indexed keywords

AROMATIC CARBON; AROMATIC OXYGEN; AROMATIC RINGS; CARBON ATOMS; CELL SURVIVAL; CELL-CYCLE PROGRESSION; CHEMICAL VARIATIONS; CLASSIFICATION MODELS; DESCRIPTORS; DEVELOPED MODEL; FRAGMENT LENGTHS; HYDROGEN BOND ACCEPTORS; HYDROGEN BOND DONORS; K-NEAREST NEIGHBOURS; KINASE INHIBITORS; MOLECULAR BRANCHING; POLAR SURFACE AREAS; PROTEIN KINASE; PROTEIN KINASE B; QSAR ANALYSIS; SIGNALLING PROTEINS; STRUCTURAL REQUIREMENTS; STRUCTURE-ACTIVITY; TOPOLOGICAL DESCRIPTORS;

AROMATIC COMPOUNDS; HYDROGEN; HYDROGEN BONDS; MOLECULAR OXYGEN; OLEFINS; TOPOLOGY;

PROTEINS;

OXYGEN; PROTEIN; PROTEIN KINASE B ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HYDROGEN BOND; MOLECULAR INTERACTION; MOLECULAR SIZE; MOLECULAR WEIGHT; MULTIPLE REGRESSION; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

LEAST-SQUARES ANALYSIS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 76749138473     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2010.01.007     Document Type: Article

References (36)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
2. Lev D.C., Kim L.S., Melnikova V., Ruiz M., Ananthaswamy H.N., and Price J.E. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br. J. Cancer 91 (2004) 795-802
3. Kumar C.C., Diao R., Yin Z., Liu Y., Samatar A.A., Madison V., and Xiao L. Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim. Biophys. Acta 1526 (2001) 257-268
4. Hsu J.H., Shi Y., Hu L.P., Fisher M., Franke T.F., and Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 21 (2002) 1391-1400
5. Page C., Lin H., Jin Y., Castle V.P., Nunez G., Huang M., and Lin J. Overexpression of Akt/AKT can modulate chemotherapy induced apoptosis. Anticancer Res. 20 (2000) 407-416
6. Okano J., Gaslightwala I., Birnbaum M.J., Rustgi A.K., and Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem. 275 (2000) 30934-33942
7. Beresford S.A., Davies M.A., Gallick G.E., and Donato N.J. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PC-3 prostate cancer cells. J. Interferon Cytokine Res. 21 (2001) 313-322
8. Li Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. Ther. Patents 17 (2007) 1077-1130
9. Lindsley C., Zhao Z., Leister, William H., Robinson R., Barnett S., Defeo-Jones D., Jones R., Hartman G., Huff J., Huber H., and Duggan M. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 761-764
10. Breitenlechner C.B., Friebe W.G., Brunet E., Werner G., Graul K., Thomas U., Künkele K.P., Schäfer W., Gassel M., Bossemeyer D., Huber R., Engh R.A., and Masjost B. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 48 (2005) 163-170
11. Breitenlechner C.B., Wegge T., Berillon L., Graul K., Marzenell K., Friebe W.G., Thomas U., Schumacher R., Huber R., Engh R.A., and Masjost B. Structure based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 47 (2004) 1375-1390
12. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., Oleksijew A., Mitten M.J., Shi Y., Guan R., McGonigal T.P., Klinghofer V., Johnson E.F., Leverson J.D., Bouska J.J., Mamo M., Smith R.A., Gramling-Evans E.E., Zinker B.A., Mika A.K., Nguyen P.T., Oltersdorf T., Rosenberg S.H., Li Q., and Giranda V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4 (2005) 977-986
13. Deanda F., Stewart E.L., Reno M.J., and Drewry D.H. Kinase-targeted library design through the application of the PharmPrint methodology. J. Chem. Inf. Model. 48 (2008) 2395-2403
14. Muddassar M., Pasha F.A., Neaz M.M., Saleem Y., and Cho S.J. Binding mode elucidation and three dimensional quantitative structure activity relationship studies on novel series of protein kinase B/Akt inhibitors. J. Mol. Mod. 15 (2009) 183-192
15. Dong X., Jiang C., Hu H., Yan J., Chen J., and Hu Y. QSAR study of Akt/protein kinase B (PKB) inhibitors using support vector machine. Eur. J. Med. Chem. 44 (2009) 4090-4097
16. Ajmani S., Jadhav K., and Kulkarni S.A. Group-Based QSAR (GQSAR): mitigating interpretation challenges in QSAR. QSAR Comb. Sci. 28 (2009) 36-41
17. VLifeMDS, Version 3.5, VLife Sciences Technologies Pvt. Ltd., Pune, India, (2008).
18. Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., Duggan M.E., and Lindsley C.W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 905-909
19. Li Q., Woods K.W., Thomas S., Zhu G.D., Packard G., Fisher J., Li T., Gong J., Dinges J., Song X., Abrams J., Luo Y., Johnson E.F., Shi Y., Liu X., Klinghofer V., de Jong R., Oltersdorf T., Stoll V.S., Jakob C.G., Rosenberg S.H., and Giranda V.L. Synthesis and structure-activity relationship of 3,4′-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorg. Med. Chem. Lett. 16 (2006) 2000-2007
20. Forino M., Jung D., Easton J.B., Houghton P.J., and Pellecchia M. Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 48 (2005) 2278-2281
21. Zhu G.D., Gong J., Claiborne A., Woods K.W., Gandhi V.B., Thomas S., Luo Y., Liu X., Shi Y., Guan R., Magnone S.R., Klinghofer V., Johnson E.F., Bouska J., Shoemaker A., Oleksijew A., Stoll V.S., De Jong R., Oltersdorf T., Li Q., Rosenberg S.H., and Giranda V.L. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorg. Med. Chem. Lett. 16 (2006) 3150-3155
22. Zhu G.D., Gandhi V.B., Gong J., Luo Y., Liu X., Shi Y., Guan R., Magnone S.R., Klinghofer V., Johnson E.F., Bouska J., Shoemaker A., Oleksijew A., Jarvis K., Park C., Jong R.D., Oltersdorf T., Li Q., Rosenberg S.H., and Giranda V.L. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg. Med. Chem. Lett. 16 (2006) 3424-3429
23. Zhu G.D., Gong J., Gandhi V.B., Woods K., Luo Y., Liu X., Guan R., Klinghofer V., Johnson E.F., Stoll V.S., Mamo M., Li Q., Rosenberg S.H., and Giranda V.L. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. 15 (2007) 2441-2452
24. Foloppe N., Fisher L.M., Francis G., Howes R., Kierstan P., and Potter A. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg. Med. Chem. 14 (2006) 1792-1804
25. Li Q., Li T., Zhu G.D., Gong J., Claibone A., Dalton C., Luo Y., Johnson E.F., Shi Y., Liu X., Klinghofer V., Bauch J.L., Marsh K.C., Bouska J.J., Arries S., De Jong R., Oltersdorf T., Stoll V.S., Jakob C.G., Rosenberg S.H., and Giranda V.L. Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 16 (2006) 1679-1685
26. Zhu G.D., Gandhi V.B., Gong J., Thomas S., Woods K.W., Song X., Li T., Diebold R.B., Luo Y., Liu X., Guan R., Klinghofer V., Johnson E.F., Bouska J., Olson A., Marsh K.C., Stoll V.S., Mamo M., Polakowski J., Campbell T.J., Martin R.L., Gintant G.A., Penning T.D., Li Q., Rosenberg S.H., and Giranda V.L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J. Med. Chem. 50 (2007) 2990-3003
27. Liu T., Lin Y., Wen X., Jorissen R.N., and Gilson M.K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35 (2007) D198-D201. http://www.bindingdb.org/bind/index.jsp
28. Baumann K. An alignment-independent versatile structure descriptor for QSAR and QSPR based on the distribution of molecular features. J. Chem. Inf. Comput. Sci. 42 (2002) 26-35
29. Golbraikh A., and Tropsha A. QSAR modeling using chirality descriptors derived from molecular topology. J. Chem. Inf. Comput. Sci. 43 (2003) 144-154
30. Kirkpatrick S., Gelatt Jr. C.D., and Vecchi M.P. Optimization by simulated annealing. Science 220 (1983) 671-680
31. Wold S. PLS for multivariate linear modelling. In: van de Waterbeemd H. (Ed). QSAR-Chemometric Methods in Molecular Design vol. 2 (1995), Wiley-VCH, Weinheim, Germany 195-218
32. Wold S., Ruhe A., Wold H., and Dunn W.J. The collinearity problem in linear regression. the partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat. Comp. 5 (1984) 735-743
33. Sharaf M.A., Illman D.L., and Kowalski B.R. Chemometrics, Chemical Analysis Series (1986), Wiley, New York
34. Zheng W., and Tropsha A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest neighbor principle. J. Chem. Inf. Comput. Sci. 40 (2000) 185-194
35. Shen M., Xiao Y., Golbraikh A., Gombar V.K., and Tropsha A. An in silico screen for human S9 metabolic turnover using k-nearest neighbor QSPR method. J. Med. Chem. 46 (2003) 3013-3020
36. Akritopoulou-Zanze I., and Hajduk P.J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today 14 (2009) 291-297